Melanoma Management最新文献_第10页

Survivor and patient advocate: an interview with T.J. Sharpe. 幸存者和病人的倡导者:对T.J.夏普的采访。

IF 3.6

Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-31 DOI: 10.2217/mmt-2017-0012

Thomas J Sharpe

{"title":"Survivor and patient advocate: an interview with T.J. Sharpe.","authors":"Thomas J Sharpe","doi":"10.2217/mmt-2017-0012","DOIUrl":"https://doi.org/10.2217/mmt-2017-0012","url":null,"abstract":"T.J. Sharpe speaks to Sebastian Dennis-Beron, Commissioning Editor: T.J. Sharpe is a stage IV melanoma patient who shares his journey through cancer in the Patient #1 Blog [1]. He was diagnosed in August 2012 with melanoma tumors in multiple organs; since then, he has undergone six surgeries and four immunotherapy treatments over two different clinical trials. The initial failures and subsequent significantly positive response have been chronicled in his blog posts since January 2013. His story is about life with a serious illness, and the mental and emotional hurdles a patient must clear. He writes how a cancer patient's challenges mirror those many face, and portrays life through the optimistic prism of a patient who is on the long, winding road toward overcoming melanoma's long odds and deadly consequences. He also shares the latest melanoma and oncology research breakthroughs and advocacy events, and initiatives to help others avoid, detect or educate themselves on cancer. As part of his advocacy, he attends cancer and melanoma conferences, reporting on the latest medical breakthroughs through his blog to other cancer patients. He also partners with advocacy organizations, clinical trial groups and the pharmaceutical industry to bring awareness to cancer research and developments. His efforts have been recognized by several organizations, including the Melanoma Research Foundation, Melanoma International Foundation, Patient Power, Forbes, Merck, GlaxoSmithKline, the Drug Information Association and the Milken Institute's FasterCures. In December 2014, he was able to share his story on Capitol Hill in a special session promoting immunotherapy research to lawmakers. A South Jersey native, T.J. lives in Fort Lauderdale with his wife Jennifer and two young children, Josie and Tommy. He is active in health and wellness initiatives, including melanoma/cancer awareness runs and bike rides, and an avid yoga participant. He also serves on the Board of Directors of A Prom to Remember, a 501","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"4 3","pages":"157-160"},"PeriodicalIF":3.6,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36470684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. ipilimumab在抗pd -1治疗进展的黑色素瘤患者中的应用

IF 3.6

Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-07-26 DOI: 10.2217/mmt-2017-0010

Cesar E Ochoa, Richard W Joseph

引用次数: 8

Are PD-1 antibodies safe for use in metastatic uveal melanoma? PD-1抗体用于转移性葡萄膜黑色素瘤安全吗?

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-10 DOI: 10.2217/mmt-2017-0007

Katy K Tsai, Alain P Algazi

引用次数: 0

Melanoma treatment guided by a panel of microRNA biomarkers. 由一组microRNA生物标志物指导的黑色素瘤治疗。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-10 DOI: 10.2217/mmt-2017-0006

Mitchell S Stark

引用次数: 1

When to consider alternatives to front-line immune therapies in metastatic melanoma. 在转移性黑色素瘤中，何时考虑替代一线免疫疗法。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 DOI: 10.2217/mmt-2017-0005

Daniel Y Wang, Douglas B Johnson

引用次数: 0

Malignant melanoma of the small bowel presenting with intussusception in a woman: a case report. 女性小肠恶性黑色素瘤伴肠套叠一例报告。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-15 DOI: 10.2217/mmt-2016-0028

Abby Vrable, Richard Chang

引用次数: 6

Making melanoma therapy personal: an interview with Dr Keiran Smalley for Melanoma Management. 使黑色素瘤治疗个人化:采访Keiran Smalley博士为黑色素瘤管理。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-19 DOI: 10.2217/mmt-2017-0001

Keiran Sm Smalley

{"title":"Making melanoma therapy personal: an interview with Dr Keiran Smalley for Melanoma Management.","authors":"Keiran Sm Smalley","doi":"10.2217/mmt-2017-0001","DOIUrl":"https://doi.org/10.2217/mmt-2017-0001","url":null,"abstract":"Dr Smalley earned his PhD in Pharmacology from the University of Cambridge, UK, in 2001. He worked as a post-doctoral fellow in the Oncology Department of University College London, the Institute of Cancer Research, Fulham Road and the Wistar Institute, PA, USA. Currently, Dr Smalley is a Professor in the Departments of Tumor Biology and Cutaneous Oncology at the Moffitt Cancer Center, FL, USA. He is also currently the Donald A Adam Endowed Chair in Melanoma Research and is the Director of the Melanoma and Skin Cancers Center of Excellence. The lab of Dr Smalley focuses upon the development of targeted therapy strategies for melanoma and is currently funded by the NCI, the pharmaceutical industry and a number of philanthropic sources. Dr Smalley's work is highly translational in nature and work from his lab has led to the initiation of a number of clinical trials. To date, Dr Smalley has published over 120 papers in top peer-reviewed journals including Cancer Research, Cancer Discovery, Cancer Cell, New England Journal of Medicine, the Proceedings of the National Academy of Sciences, the Lancet, Gastroenterology and Clinical Cancer Research. He currently sits on the editorial boards of Clinical Cancer Research, Biochemical Pharmacology, Drugs, Melanoma Research and the American Journal of Clinical Dermatology and is the Associate Editor of Pharmacological Research. Dr Smalley is a charter member of the Basic Mechanisms of Cancer Therapeutics Study Section for the NCI/NIH and has served on many other peer review panels for the Department of Defense, the state of Texas and numerous melanoma research foundations. He has also fulfilled advisory roles with the University of Pennsylvania, the University of Pittsburgh and a number of pharmaceutical companies. Dr Smalley has been a visiting professor at the University of Sao Paulo, Brazil in 2011 and in 2014 received a Science Without Borders Scholarship from the Brazilian Government.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":" ","pages":"95-97"},"PeriodicalIF":3.6,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Patient perspective: life in the melanoma patient community and the emergence of the melanoma patient conference. 患者视角:黑色素瘤患者社区的生活和黑色素瘤患者会议的出现。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-19 DOI: 10.2217/mmt-2017-0011

Imogen Cheese

{"title":"Patient perspective: life in the melanoma patient community and the emergence of the melanoma patient conference.","authors":"Imogen Cheese","doi":"10.2217/mmt-2017-0011","DOIUrl":"https://doi.org/10.2217/mmt-2017-0011","url":null,"abstract":"Imogen Cheese speaks to Sebastian Dennis-Beron, Commissioning Editor: Imogen was diagnosed with melanoma in June 2013 (currently stage 2C no evidence of disease monitored under Professor Mark Middleton at Oxford) and has since created and writes a website blog (www.melanomarollercoaster.co.uk) as well as founded the melanoma patient conference in 2015. As an impartial event, the patient conference brings together all stakeholders involved in melanoma diagnosis, treatment and care; this includes clinicians, charities and crucially, people living and dying with melanoma. This means the only end goal for the conference are the ongoing needs of patients and families. Imogen's blog has a readership of over 2000 people - many of whom are melanoma patients in the UK. She is prolific in her contact with these patients on social media and as a result of her blog, she has been asked to represent melanoma patients in the UK as their advocacy representative at numerous conferences and events across Europe (including ECC2015 and the MPNE annual events in Brussels). Patients reach out to Imogen on a daily basis asking for support and seeking a means to improve their knowledge and obtain access to better care and information on the latest drugs and trials in the UK. She is a member of the Melanoma Patient Network Europe and speaks daily to over 300 patients on an online support group on social media. Imogen was invited by the British Skin Foundation to support them in establishing a skin cancer specific arm of their charity called ITTakes7 and has worked directly with Melanoma UK on various projects for patient interaction and information gathering. She is connected with Cancer Research UK as a patient representative with the ECMC network and involved with the Oxford hospitals as an advisor for their public engagement and planning. Imogen can be found on twitter at @MelanomaBlog.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":" ","pages":"89-93"},"PeriodicalIF":3.6,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2017-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36468068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving the diagnosis and treatment of acral melanocytic lesions. 提高肢端黑色素细胞病变的诊断和治疗水平。

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-19 DOI: 10.2217/mmt-2016-0017

Maressa C Criscito, Jennifer A Stein

引用次数: 14

What is new in melanoma after European Cancer Congress 2017? 2017年欧洲癌症大会后黑色素瘤有什么新进展?

IF 3.6

Melanoma Management Pub Date : 2017-05-01 Epub Date: 2017-05-15 DOI: 10.2217/mmt-2017-0004

Piotr Rutkowski

引用次数: 0